Influence of isosorbide-5-mononitrate on the circadian rhythm of angina pectoris.
Efficacy and safety of two different dose regimens of isosorbide-5-mononitrate (isosorbide mononitrate, ISMN, Mono Mack, CAS 16051-77-7) (40 mg ISMN in the morning, n = 187 vs. 20 mg ISMN b.i.d. morning and early afternoon, n = 195) were evaluated in an open, randomised study in patients with symptomatic myocardial ischemia. Circadian rate, frequency, severity and duration of angina pectoris attacks, as well as the additional need of short-acting nitrates were assessed on 3 consecutive days before and at the end of the first and second weeks of treatment, respectively. In both treatment groups, a statistically significant decrease of frequency and severity of angina pectoris attacks was observed as compared to baseline. Apart from minor variations, no statistically significant differences were found between the two treatment groups.
Ganzinger
U
U
Medical Department, Pfizer Med Inform GesmbH, Vienna, Austria.
D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy* / Q000503:physiopathology; D002940:Circadian Rhythm / Q000187:drug effects*; D003327:Coronary Disease / Q000188:drug therapy / Q000503:physiopathology; D004562:Electrocardiography; D005260:Female; D006801:Humans; D007548:Isosorbide Dinitrate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male
D007548:Isosorbide Dinitrate; C030397:isosorbide-5-mononitrate